All Data
Lead Product(s): W0180,Pembrolizumab
Therapeutic Area: Oncology Product Name: W0180
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
W0180 is a first-in-class antibody targeting VISTA (V-domain Ig suppressor of T cell Activation). VISTA is a negative checkpoint regulator of T cell response.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Valemetostat
Therapeutic Area: Oncology Product Name: DS-3201
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Daiichi Sankyo Co Ltd
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 24, 2021
Details:
The partnership brings together Daiichi Sankyo, the Lymphoma Academic Research Organization, and the CALYM research alliance to perform clinical and translational research on valemetostat in patients with relapsed/refractory non-Hodgkin lymphoma.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TG4050
Therapeutic Area: Oncology Product Name: TG4050
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: NEC Corporation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 21, 2021
Details:
First patient with head and neck cancer has been dosed with the Company’s innovative individualized immunotherapy, TG4050. The vaccine is based on Transgene’s myvac® technology platform, which leverages cutting-edge AI capabilities to customize the treatment for each patient.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): UCART22,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: UCART22
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2020
Details:
UCART22 demonstrated preliminary signs of activity at low dose levels with fludarabine/cyclophosphamide (FC) lymphodepletion regimen, without unexpected nor significant treatment-related toxicities.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): UCARTCS1
Therapeutic Area: Oncology Product Name: UCARTCS1
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2020
Details:
Cellectis worked closely with the FDA over the past months, to address the agency’s requests, which include adjustments to the MELANI-01 clinical protocol designed to enhance patient safety.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Hafnium dioxide,Undisclosed
Therapeutic Area: Oncology Product Name: NBTXR3
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 12, 2020
Details:
NBTXR3 activated by radiation therapy produced a strong abscopal effect without a checkpoint inhibitor combination. NBTXR3 activated by radiation therapy stimulated adaptive antitumor immunity.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
